Article

Does on-demand vardenafil improve erectile function recovery after radical prostatectomy?

Sexual and Reproductive Medicine, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Nature Clinical Practice Urology (Impact Factor: 4.07). 01/2009; 6(1):14-5. DOI: 10.1038/ncpuro1271
Source: PubMed

ABSTRACT The randomized, placebo-controlled trial reported by Montorsi and colleagues attempted to determine if nightly vardenafil was more effective than on-demand drug in restoring erectile function after radical prostatectomy. No significant difference in outcomes was found between the study groups at 11 or 13 months after surgery. The study, however, had enough methodological flaws to prevent any definitive conclusions from being drawn. The authors' conclusion that the data support a shift towards on-demand phosphodiesterase 5 inhibitor use after radical prostatectomy is not supported by the data.

0 Bookmarks
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite a growing body of evidence supporting erectile function (EF) rehabilitation after radical prostatectomy (RP), there are no guidelines on this subject. To explore EF rehabilitation practice patterns of American Urological Association (AUA) urologists. A 35-question instrument was constructed assessing physician demographics, training, and EF rehabilitation practices after RP, and was e-mailed to AUA members by the AUA Office of Education. Data were acquired by the AUA and analyzed by the investigators. Percentage of responders who recommend EF rehabilitation practices following RP, characterization of prevalent rehabilitation practices. Of the 618 urologists who completed the survey, 71% were in private practice, 28% considered themselves as sexual medicine specialists, although only 4% were fellowship-trained, 43% were urologic oncology specialists (14% fellowship-trained), 86% performed RP, and 86% of responders recommended rehabilitation practices. Being a sexual medicine or a urologic oncology specialist was not predictive of rehabilitation employment. Forty-three percent rehabilitate all patients, 57% only selected patients. Selection for rehabilitation was dependent upon preop EF by 66%, nerve-sparing status by 22%, and age by 5%. Eleven percent started rehab immediately after RP, 97% within 4 months. 24%, 45% and 18% ceased rehab at <12, 12-18, and 18-24 months, respectively. Eighty-nine percent of RP surgeons performed rehabilitation vs. only 66% who do not perform RP (P < 0.0001). Eighty-seven percent prefer phosphodiesterase type 5 inhibitors (PDE5i) as their primary strategy followed (in order) by vacuum erection device (VED), intracavernosal injection (ICI), and urethral suppositories. Among the respondents, penile rehabilitation is a common practice. Urologic oncologists and RP surgeons are more likely to use rehabilitation practices. The most commonly employed strategy is regular PDE5i use for 12-18 months after RP. .
    Journal of Sexual Medicine 06/2011; 8(8):2370-6. DOI:10.1111/j.1743-6109.2011.02355.x · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the role of phosphodiesterase type 5 (PDE5) inhibitors in post-prostatectomy penile rehabilitation (PPPR). To compare nightly and on-demand use of PDE5 inhibitors after nerve-sparing minimally invasive radical prostatectomy (RP). We conducted a single-institution, double-blind, randomized controlled trial of nightly vs on-demand 50-mg sildenafil citrate after nerve-sparing minimally invasive RP. A total of 100 preoperatively potent men, aged <65 years, with scores on the Erectile Function domain of the International Index of Erectile Function (IIEF-EF) ≥26, underwent nerve-sparing surgery. The patients were randomized to either nightly sildenafil and on-demand placebo (nightly sildenafil group), or on-demand sildenafil and nightly placebo (on-demand sildenafil group; maximum on-demand dose six tablets/month) for 12 months. Patients then underwent a 1-month washout period. Validated measures of erectile function (IIEF-EF score and the Expanded Prostate Cancer Index Composite [EPIC]) were compared between treatment groups over the entire 13-month time course, using multivariable mixed linear regression models. The treatment groups were well matched preoperatively (mean age 54.3 vs 54.6 years, baseline IIEF-EF score 29.4 vs 29.3, for the nightly vs the on-demand sildenafil groups, respectively). No significant differences were found in erectile function between treatments (nightly vs on-demand sildenafil) at any single timepoint after RP, after adjusting for potential confounding factors. When evaluated over all timepoints simultaneously, no significant effects of treatment group (nightly vs on-demand sildenafil) were found on recovery of potency, as assessed by absolute IIEF-EF scores (P = 0.765), on percentage of men returning to an IIEF-EF score >21 (P = 0.830), or on IIEF-EF score recovery to a percentage of baseline value (P = 0.778). When evaluated over all timepoints simultaneously, no significant effects of treatment group were found on secondary endpoints such as assessment of potency (including EPIC item 59 response 'erections firm enough for intercourse'), attempted intercourse frequency or confidence. Erectile recovery up to 1 year after RP does not differ between previously potent men who use sildenafil nightly compared to on-demand. This trial does not support chronic nightly sildenafil as being any better than on-demand sildenafil for use in penile rehabilitation after nerve-sparing minimally invasive RP.
    BJU International 05/2013; DOI:10.1111/bju.12253 · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the expression pattern of CXC chemokine ligand-12 (CXCL12) in the placentae of normal and pre-eclamptic women. Twenty-five women with severe pre-eclampsia and 30 normotensive women, matched for gestational age, were enrolled in the study. Placental tissue from each woman was collected following delivery by caesarean section. Quantitative reverse transcription polymerase chain reaction, Western blot analysis and immunohistochemical staining were performed for mRNA expression, quantification and tissue localization of CXCL12 in each placenta. CXCL12 expression was greater in pre-eclamptic placentae compared with normal placentae. CXCL12 was detected in most placental tissue cells by immunohistochemical staining. CXCL12 immunoreactivity was significantly greater in syncytiotrophoblasts of pre-eclamptic placentae compared with normal placentae. However, there was no significant difference in CXCL12 immunoreactivity in other tissues between the two groups. CXCL12 expression is significantly greater in the placentae of pre-eclamptic women compared with normal women. This may represent part of a compensatory mechanism for pre-eclampsia.
    European journal of obstetrics, gynecology, and reproductive biology 11/2011; 160(2):137-41. DOI:10.1016/j.ejogrb.2011.10.007 · 1.97 Impact Factor